Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

4(50.0%)

Phase 2

3(37.5%)

Phase 1

1(12.5%)

8Total

Phase 3(4)

Phase 2(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01961960Phase 3Completed

A Study to Evaluate Intramuscular ASP7374

Role: lead

NCT01393951Phase 1Completed

A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers

Role: lead

NCT01450579Phase 2Completed

A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers

Role: lead

NCT02366962Phase 3Completed

A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older

Role: lead

NCT01961947Phase 3Completed

Study of ASP7374, Cell-culture-derived Influenza Vaccine

Role: lead

NCT01767896Phase 3Completed

Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

Role: lead

NCT01195038Phase 2Completed

Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults

Role: lead

NCT00980447Phase 2Completed

Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

Role: lead

All 8 trials loaded